
Community Acquired Pneumonia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Community Acquired Pneumonia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Community Acquired Pneumonia - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Community Acquired Pneumonia (Infectious Disease) pipeline landscape.
Community-acquired pneumonia (CAP) is defined as pneumonia acquired outside a hospital or long-term care facility. Symptoms include cough, fever, shaking chills, confusion, headache and loss of appetite. Risk factors include chronic lung disease, cigarette smoking, dementia, stroke, brain injury, heart disease, liver cirrhosis and diabetes mellitus. Treatment includes antibiotics and healthy lifestyle.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Community Acquired Pneumonia - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Community Acquired Pneumonia (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Community Acquired Pneumonia (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Community Acquired Pneumonia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 4, 6, 2, 3 and 1 respectively. Similarly, the Universities portfolio in Phase 0 stages comprises 1 molecules, respectively.
Community Acquired Pneumonia (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Community Acquired Pneumonia - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Community Acquired Pneumonia (Infectious Disease) pipeline landscape.
Community-acquired pneumonia (CAP) is defined as pneumonia acquired outside a hospital or long-term care facility. Symptoms include cough, fever, shaking chills, confusion, headache and loss of appetite. Risk factors include chronic lung disease, cigarette smoking, dementia, stroke, brain injury, heart disease, liver cirrhosis and diabetes mellitus. Treatment includes antibiotics and healthy lifestyle.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Community Acquired Pneumonia - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Community Acquired Pneumonia (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Community Acquired Pneumonia (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Community Acquired Pneumonia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 4, 6, 2, 3 and 1 respectively. Similarly, the Universities portfolio in Phase 0 stages comprises 1 molecules, respectively.
Community Acquired Pneumonia (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Community Acquired Pneumonia (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Community Acquired Pneumonia (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Community Acquired Pneumonia (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Community Acquired Pneumonia (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Community Acquired Pneumonia (Infectious Disease)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Community Acquired Pneumonia (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Community Acquired Pneumonia (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Companies Mentioned
Beijing FuKangren Bio-pharm Tech Co Ltd
BioAegis Therapeutics Inc
Biotest AG
Eagle Pharmaceuticals Inc
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
InflaRx NV
ioGenetics Inc
Iterum Therapeutics Plc
Korea Pharma Co Ltd
La Jolla Pharmaceutical Company
Meiji Seika Pharma Co Ltd
Merck & Co Inc
Nabriva Therapeutics Plc
Paratek Pharmaceuticals Inc
ProThera Biologics Inc
TaiGen Biotechnology Co Ltd
Takeda Pharmaceutical Co Ltd
Wockhardt Ltd
Companies Mentioned
Beijing FuKangren Bio-pharm Tech Co Ltd
BioAegis Therapeutics Inc
Biotest AG
Eagle Pharmaceuticals Inc
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
InflaRx NV
ioGenetics Inc
Iterum Therapeutics Plc
Korea Pharma Co Ltd
La Jolla Pharmaceutical Company
Meiji Seika Pharma Co Ltd
Merck & Co Inc
Nabriva Therapeutics Plc
Paratek Pharmaceuticals Inc
ProThera Biologics Inc
TaiGen Biotechnology Co Ltd
Takeda Pharmaceutical Co Ltd
Wockhardt Ltd
Table of Contents
94 Pages
- Introduction
- Global Markets Direct Report Coverage
- Community Acquired Pneumonia - Overview
- Community Acquired Pneumonia - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Community Acquired Pneumonia - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Community Acquired Pneumonia - Companies Involved in Therapeutics Development
- Beijing FuKangren Bio-pharm Tech Co Ltd
- BioAegis Therapeutics Inc
- Biotest AG
- Eagle Pharmaceuticals Inc
- Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
- InflaRx NV
- ioGenetics Inc
- Iterum Therapeutics Plc
- Korea Pharma Co Ltd
- La Jolla Pharmaceutical Company
- Meiji Seika Pharma Co Ltd
- Merck & Co Inc
- Nabriva Therapeutics Plc
- Paratek Pharmaceuticals Inc
- ProThera Biologics Inc
- TaiGen Biotechnology Co Ltd
- Takeda Pharmaceutical Co Ltd
- Wockhardt Ltd
- Community Acquired Pneumonia - Drug Profiles
- BT-588 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CAL-02 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ceftaroline fosamil - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ceftriamidine sodium - Drug Profile
- Product Description
- Mechanism Of Action
- Cx-611 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- DBAF-301 - Drug Profile
- Product Description
- Mechanism Of Action
- eravacycline dihydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- interferon alfa-2b - Drug Profile
- Product Description
- Mechanism Of Action
- KP-091 - Drug Profile
- Product Description
- Mechanism Of Action
- lefamulin acetate - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- nafithromycin - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- nemonoxacin - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- omadacycline tosylate - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- oxytetracycline hydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- Proteins for Community Acquired Pneumonia - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Recombinant Plasma Gelsolin Replacement for Infectious Disease - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- solithromycin - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- sulopenem - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- sulopenem etzadroxil - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- tebipenem pivoxil hydrobromide - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- vilobelimab - Drug Profile
- Product Description
- Mechanism Of Action
- Community Acquired Pneumonia - Dormant Projects
- Community Acquired Pneumonia - Discontinued Products
- Community Acquired Pneumonia - Product Development Milestones
- Featured News & Press Releases
- Dec 16, 2021: China's National Medical Products Administration approves NUZYRA (omadacycline) for the treatment of bacterial pneumonia and skin infections
- Nov 29, 2021: Lefamulin NDA filed in Mainland China for treatment of Community Acquired Pneumonia
- Oct 04, 2021: Nabriva publishes data demonstrating the potent anti-inflammatory properties of XENLETA (lefamulin)
- Sep 24, 2021: Nabriva Therapeutics to present data at IDWeek 2021
- Sep 09, 2021: Nabriva and Vizient enter into agreement to make XENLETA (lefamulin) available to Vizient’s Pharmacy Network Program
- Sep 08, 2021: Lefamulin receives approval in Taiwan for treatment of community-acquired pneumonia
- Aug 26, 2021: Wockhardt and Jemincare partner for novel respiratory antibiotic Nafithromycin
- Aug 05, 2021: Everest Medicines announces approval of clinical trial application by China NMPA for Phase 3 trial of Xerava for Community-Acquired Bacterial Pneumonia
- Jun 01, 2021: Paratek Pharmaceuticals announces FDA approval of NUZYRA (omadacycline) oral only dosing regimen for the treatment of Community-Acquired Bacterial Pneumonia (CABP)
- May 25, 2021: Sinovant Sciences and Nabriva Therapeutics announce positive topline results from phase 3 trial of Lefamulin in Chinese adults with community acquired bacterial pneumonia (CABP)
- Mar 16, 2021: Nabriva publishes clinical data analysis highlighting benefits of outpatient management of Community Acquired Bacterial Pneumonia (CABP) with oral XENLETA (lefamulin)
- Feb 23, 2021: Study demonstrates macrolide-resistance in S. pneumoniae in the United States exceeds 25 percent threshold set in current Community-Acquired Bacterial Pneumonia (CABP) treatment guidelines
- Feb 08, 2021: Paratek announces expansion of Nuzyra launch into the community setting
- Dec 07, 2020: Nabriva Therapeutics and Sinovant Sciences restructure license agreement for XENLETA for community-acquired bacterial pneumonia in China
- Oct 21, 2020: Key highlights include data on NUZYRA as an alternative to standard of care to reduce clostridioides difficile infections and real-world experience with NUZYRA for nontuberculous mycobacterial and MDR/XDR gram negative infections
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products under Development for Community Acquired Pneumonia, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Companies, 2022 (Contd..1)
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Community Acquired Pneumonia - Pipeline by Beijing FuKangren Bio-pharm Tech Co Ltd, 2022
- Community Acquired Pneumonia - Pipeline by BioAegis Therapeutics Inc, 2022
- Community Acquired Pneumonia - Pipeline by Biotest AG, 2022
- Community Acquired Pneumonia - Pipeline by Eagle Pharmaceuticals Inc, 2022
- Community Acquired Pneumonia - Pipeline by Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd, 2022
- Community Acquired Pneumonia - Pipeline by InflaRx NV, 2022
- Community Acquired Pneumonia - Pipeline by ioGenetics Inc, 2022
- Community Acquired Pneumonia - Pipeline by Iterum Therapeutics Plc, 2022
- Community Acquired Pneumonia - Pipeline by Korea Pharma Co Ltd, 2022
- Community Acquired Pneumonia - Pipeline by La Jolla Pharmaceutical Company, 2022
- Community Acquired Pneumonia - Pipeline by Meiji Seika Pharma Co Ltd, 2022
- Community Acquired Pneumonia - Pipeline by Merck & Co Inc, 2022
- Community Acquired Pneumonia - Pipeline by Nabriva Therapeutics Plc, 2022
- Community Acquired Pneumonia - Pipeline by Paratek Pharmaceuticals Inc, 2022
- Community Acquired Pneumonia - Pipeline by ProThera Biologics Inc, 2022
- Community Acquired Pneumonia - Pipeline by TaiGen Biotechnology Co Ltd, 2022
- Community Acquired Pneumonia - Pipeline by Takeda Pharmaceutical Co Ltd, 2022
- Community Acquired Pneumonia - Pipeline by Wockhardt Ltd, 2022
- Community Acquired Pneumonia - Dormant Projects, 2022
- Community Acquired Pneumonia - Dormant Projects, 2022 (Contd..1)
- Community Acquired Pneumonia - Discontinued Products, 2022
- List of Figures
- Number of Products under Development for Community Acquired Pneumonia, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.